Reagent kit for detecting endometrial cancer susceptibility related genetic marker

Abstract

The invention discloses a reagent kit for detecting an endometrial cancer susceptibility related genetic marker, and belongs to the technical field of molecular biology and biological medicine. The nucleotide sequence of the genetic marker is as shown in SEQID NO.1, single nucleotide polymorphism that T is greater than G exists in the 501st of the nucleotide sequence, namely that the 501st basic group of the sequence comprises two situations of a basic group T and a basic group G. The reagent kit provided by the invention contains 2 pairs of specific PCR primers designed based on single nucleotide polymorphism of a POU5F1 gene, the single nucleotide polymorphism of the POU5F1 gene is closely related to susceptibility that people suffer from endometrial cancer, through a PCR technique, thesingle nucleotide polymorphism in the POU5F1 gene can be effectively detected, and further the susceptibility of the endometrial cancer is predicted, so that the reagent kit has important clinical significance in screening endometrial cancer susceptible population, detecting high-risk individuals, and performing early prediction, early diagnosis and individualized treatment of the endometrial cancer.

Description

technical field [0001] The invention relates to the technical fields of molecular biology and biomedicine, in particular to a kit for detecting the genetic marker of the single nucleotide polymorphism of the endometrial cancer susceptibility-related POU5F1 gene. Background technique [0002] Endometrial cancer is one of the most common gynecological tumors in the world. Its incidence has been increasing over the past few decades and tends to be younger, especially in developed countries. According to the FIGO 2009 classification, 80% of endometrial cancers are clinical stage I-II when diagnosed, the 5-year survival rate of stage I is 89.6%, that of stage II drops to 78.3%, that of stage III is 61.9%, and that of stage IV is 21.1%. Although endometrial cancer diagnosed early can be cured with surgery plus adjuvant radiotherapy or chemotherapy, approximately 15% of patients will relapse and progress. [0003] The etiology of endometrial cancer remains unclear due to the comp...

AI Technical Summary

Problems solved by technology

So far, highly expressed POU5F1 protein has been detected in cancer cells of various tumors. Although the detection of the protein level cannot effectively predict and diagnose the disease in the early stage, it suggests that it is possible for us to detect the genetic background of the POU5F1 gene at the DNA level. Molecular markers for early prediction of tumors discovered

Images